Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 120

1.

Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: Response, Progression, and Pseudoprogression.

Galldiks N, Kocher M, Ceccon G, Werner JM, Brunn A, Deckert M, Pope WB, Soffietti R, Le Rhun E, Weller M, Tonn JC, Fink GR, Langen KJ.

Neuro Oncol. 2019 Aug 22. pii: noz147. doi: 10.1093/neuonc/noz147. [Epub ahead of print]

PMID:
31437274
2.

Association between Tumor Acidity and Hypervascularity in Human Gliomas Using pH-Weighted Amine Chemical Exchange Saturation Transfer Echo-Planar Imaging and Dynamic Susceptibility Contrast Perfusion MRI at 3T.

Wang YL, Yao J, Chakhoyan A, Raymond C, Salamon N, Liau LM, Nghiemphu PL, Lai A, Pope WB, Nguyen N, Ji M, Cloughesy TF, Ellingson BM.

AJNR Am J Neuroradiol. 2019 Jun;40(6):979-986. doi: 10.3174/ajnr.A6063. Epub 2019 May 16.

PMID:
31097430
3.

Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI.

Yao J, Chakhoyan A, Nathanson DA, Yong WH, Salamon N, Raymond C, Mareninov S, Lai A, Nghiemphu PL, Prins RM, Pope WB, Everson RG, Liau LM, Cloughesy TF, Ellingson BM.

Neuro Oncol. 2019 May 4. pii: noz078. doi: 10.1093/neuonc/noz078. [Epub ahead of print]

PMID:
31066901
4.

Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry.

Chakhoyan A, Yao J, Leu K, Pope WB, Salamon N, Yong W, Lai A, Nghiemphu PL, Everson RG, Prins RM, Liau LM, Nathanson DA, Cloughesy TF, Ellingson BM.

Sci Rep. 2019 Feb 26;9(1):2846. doi: 10.1038/s41598-018-37564-w.

5.

pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma.

Yao J, Tan CHP, Schlossman J, Chakhoyan A, Raymond C, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM.

J Neurooncol. 2019 May;142(3):587-595. doi: 10.1007/s11060-019-03132-z. Epub 2019 Feb 26.

PMID:
30806888
6.

Longitudinal MRI findings in patients with newly diagnosed glioblastoma after intraoperative radiotherapy.

Förster A, Böhme J, Maros ME, Brehmer S, Seiz-Rosenhagen M, Hänggi D, Wenz F, Groden C, Pope WB, Giordano FA.

J Neuroradiol. 2019 Jan 16. pii: S0150-9861(18)30283-9. doi: 10.1016/j.neurad.2019.01.090. [Epub ahead of print]

PMID:
30659892
7.

Improving B0 Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation.

Yao J, Ruan D, Raymond C, Liau LM, Salamon N, Pope WB, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM.

Tomography. 2018 Sep;4(3):123-137. doi: 10.18383/j.tom.2018.00017.

9.

Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.

Ellingson BM, Abrey LE, Garcia J, Chinot O, Wick W, Saran F, Nishikawa R, Henriksson R, Mason WP, Harris RJ, Leu K, Woodworth DC, Mehta A, Raymond C, Chakhoyan A, Pope WB, Cloughesy TF.

Neuro Oncol. 2018 Oct 9;20(11):1525-1535. doi: 10.1093/neuonc/noy064.

10.

Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma.

Chakhoyan A, Woodworth DC, Harris RJ, Lai A, Nghiemphu PL, Liau LM, Pope WB, Cloughesy TF, Ellingson BM.

J Neurooncol. 2018 Sep;139(3):651-659. doi: 10.1007/s11060-018-2910-9. Epub 2018 May 31.

11.
12.

Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.

Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, Kaprealian T, Pope WB, Nghiemphu PL, Cloughesy T, Lassman A, Lai A.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1195-1203. doi: 10.1016/j.ijrobp.2018.01.001. Epub 2018 Jan 6. Erratum in: Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1289.

13.

Conventional and advanced magnetic resonance imaging in patients with high-grade glioma.

Pope WB, Brandal G.

Q J Nucl Med Mol Imaging. 2018 Sep;62(3):239-253. doi: 10.23736/S1824-4785.18.03086-8. Epub 2018 Apr 26. Review.

14.

Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF.

Neuro Oncol. 2018 Aug 2;20(9):1240-1250. doi: 10.1093/neuonc/noy053.

15.

Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI).

Harris RJ, Yao J, Chakhoyan A, Raymond C, Leu K, Liau LM, Nghiemphu PL, Lai A, Salamon N, Pope WB, Cloughesy TF, Ellingson BM.

Magn Reson Med. 2018 Nov;80(5):1962-1978. doi: 10.1002/mrm.27204. Epub 2018 Apr 6.

16.

Brain metastases: neuroimaging.

Pope WB.

Handb Clin Neurol. 2018;149:89-112. doi: 10.1016/B978-0-12-811161-1.00007-4. Review.

17.

Gadolinium deposition in the paediatric brain: T1-weighted hyperintensity within the dentate nucleus following repeated gadolinium-based contrast agent administration.

Young JR, Orosz I, Franke MA, Kim HJ, Woodworth D, Ellingson BM, Salamon N, Pope WB.

Clin Radiol. 2018 Mar;73(3):290-295. doi: 10.1016/j.crad.2017.11.005. Epub 2017 Dec 6.

18.

Application of arterial spin labeling perfusion MRI to differentiate benign from malignant intracranial meningiomas.

Qiao XJ, Kim HG, Wang DJJ, Salamon N, Linetsky M, Sepahdari A, Ellingson BM, Pope WB.

Eur J Radiol. 2017 Dec;97:31-36. doi: 10.1016/j.ejrad.2017.10.005. Epub 2017 Oct 7.

19.

Improved Spatiotemporal Resolution of Dynamic Susceptibility Contrast Perfusion MRI in Brain Tumors Using Simultaneous Multi-Slice Echo-Planar Imaging.

Chakhoyan A, Leu K, Pope WB, Cloughesy TF, Ellingson BM.

AJNR Am J Neuroradiol. 2018 Jan;39(1):43-45. doi: 10.3174/ajnr.A5433. Epub 2017 Oct 26.

20.

Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.

Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF.

Clin Cancer Res. 2017 Oct 1;23(19):5745-5756. doi: 10.1158/1078-0432.CCR-16-2844. Epub 2017 Jun 27.

21.

Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.

Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, Liau LM, Cloughesy TF, Ellingson BM.

J Neurooncol. 2017 Aug;134(1):177-188. doi: 10.1007/s11060-017-2506-9. Epub 2017 May 25.

22.

Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape.

Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ.

J Neurooncol. 2017 Sep;134(3):495-504. doi: 10.1007/s11060-017-2375-2. Epub 2017 Apr 5. Review.

23.

The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy.

Galldiks N, Law I, Pope WB, Arbizu J, Langen KJ.

Neuroimage Clin. 2016 Dec 18;13:386-394. doi: 10.1016/j.nicl.2016.12.020. eCollection 2017. Review.

24.

Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3 T.

Harris RJ, Cloughesy TF, Liau LM, Nghiemphu PL, Lai A, Pope WB, Ellingson BM.

NMR Biomed. 2016 Nov;29(11):1563-1576. doi: 10.1002/nbm.3611. Epub 2016 Sep 15.

PMID:
27717216
25.

Dynamic Susceptibility Contrast MR Imaging in Glioma: Review of Current Clinical Practice.

Boxerman JL, Shiroishi MS, Ellingson BM, Pope WB.

Magn Reson Imaging Clin N Am. 2016 Nov;24(4):649-670. doi: 10.1016/j.mric.2016.06.005. Epub 2016 Sep 14. Review.

PMID:
27742108
26.

Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.

Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF.

Neuro Oncol. 2017 Jan;19(1):89-98. doi: 10.1093/neuonc/now187. Epub 2016 Aug 31.

27.

Blood-Labyrinth Barrier Permeability in Menière Disease and Idiopathic Sudden Sensorineural Hearing Loss: Findings on Delayed Postcontrast 3D-FLAIR MRI.

Pakdaman MN, Ishiyama G, Ishiyama A, Peng KA, Kim HJ, Pope WB, Sepahdari AR.

AJNR Am J Neuroradiol. 2016 Oct;37(10):1903-1908. doi: 10.3174/ajnr.A4822. Epub 2016 Jun 2.

28.

Improved Leakage Correction for Single-Echo Dynamic Susceptibility Contrast Perfusion MRI Estimates of Relative Cerebral Blood Volume in High-Grade Gliomas by Accounting for Bidirectional Contrast Agent Exchange.

Leu K, Boxerman JL, Cloughesy TF, Lai A, Nghiemphu PL, Liau LM, Pope WB, Ellingson BM.

AJNR Am J Neuroradiol. 2016 Aug;37(8):1440-6. doi: 10.3174/ajnr.A4759. Epub 2016 Apr 14.

29.

Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma.

Ellingson BM, Nguyen HN, Lai A, Nechifor RE, Zaw O, Pope WB, Yong WH, Nghiemphu PL, Liau LM, Cloughesy TF.

Cancer. 2016 Jun 1;122(11):1718-27. doi: 10.1002/cncr.29957. Epub 2016 Mar 21.

30.

Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab.

Leu K, Boxerman JL, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM.

J Magn Reson Imaging. 2016 Nov;44(5):1229-1237. doi: 10.1002/jmri.25227. Epub 2016 Mar 12.

31.

Neuroimaging.

Pope WB, Djoukhadar I, Jackson A.

Handb Clin Neurol. 2016;134:27-50. doi: 10.1016/B978-0-12-802997-8.00003-7. Review.

PMID:
26948347
32.

Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma.

Chang W, Pope WB, Harris RJ, Hardy AJ, Leu K, Mody RR, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM.

Tomography. 2015 Sep;1(1):37-43.

33.

Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping.

Banerjee P, Leu K, Harris RJ, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB, Bookheimer SY, Ellingson BM.

Neuroimage Clin. 2015 Oct 23;9:617-24. doi: 10.1016/j.nicl.2015.10.010. eCollection 2015.

34.

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA.

Lancet Oncol. 2015 Nov;16(15):e534-e542. doi: 10.1016/S1470-2045(15)00088-1. Review.

35.

The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab.

Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY.

Clin Cancer Res. 2016 Feb 1;22(3):575-81. doi: 10.1158/1078-0432.CCR-14-3040. Epub 2015 Oct 21.

36.

Evidence for rCBV as an early response marker following bevacizumab treatment.

Pope WB.

Neuro Oncol. 2015 Nov;17(11):1539-40. doi: 10.1093/neuonc/nov199. No abstract available.

37.

Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Shiroishi MS, Boxerman JL, Pope WB.

Neuro Oncol. 2016 Apr;18(4):467-78. doi: 10.1093/neuonc/nov179. Epub 2015 Sep 12. Review.

38.

Standardized Brain Tumor Imaging Protocol for Clinical Trials.

Goldmacher GV, Ellingson BM, Boxerman J, Barboriak D, Pope WB, Gilbert M.

AJNR Am J Neuroradiol. 2015 Oct;36(10):E65-6. doi: 10.3174/ajnr.A4544. Epub 2015 Sep 10. No abstract available.

39.

Two cases of rheumatoid meningitis.

Magaki S, Chang E, Hammond RR, Yang I, Mackenzie IR, Chou BT, Choi SI, Jen JC, Pope WB, Bell DA, Vinters HV.

Neuropathology. 2016 Feb;36(1):93-102. doi: 10.1111/neup.12238. Epub 2015 Sep 8.

PMID:
26350538
40.

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR; Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee.

Neuro Oncol. 2015 Sep;17(9):1188-98. doi: 10.1093/neuonc/nov095. Epub 2015 Aug 5. Review.

41.

From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors?

Galldiks N, Langen KJ, Pope WB.

Neuro Oncol. 2015 Nov;17(11):1434-44. doi: 10.1093/neuonc/nov118. Epub 2015 Jun 30. Review.

42.

pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI.

Harris RJ, Cloughesy TF, Liau LM, Prins RM, Antonios JP, Li D, Yong WH, Pope WB, Lai A, Nghiemphu PL, Ellingson BM.

Neuro Oncol. 2015 Nov;17(11):1514-24. doi: 10.1093/neuonc/nov106. Epub 2015 Jun 24.

43.

Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma.

Hathout L, Pope WB, Lai A, Nghiemphu PL, Cloughesy TF, Ellingson BM.

CNS Oncol. 2015;4(4):247-56. doi: 10.2217/cns.15.16. Epub 2015 Jun 22.

44.

Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth.

Hathout L, Ellingson BM, Cloughesy TF, Pope WB.

Oncol Rep. 2015 Jun;33(6):2883-8. doi: 10.3892/or.2015.3926. Epub 2015 Apr 27.

PMID:
25962999
45.

Predictive imaging marker of bevacizumab efficacy: perfusion MRI.

Pope WB.

Neuro Oncol. 2015 Aug;17(8):1046-7. doi: 10.1093/neuonc/nov067. Epub 2015 Apr 24. No abstract available.

46.

Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI.

Ellingson BM, Lai A, Nguyen HN, Nghiemphu PL, Pope WB, Cloughesy TF.

Clin Cancer Res. 2015 Oct 1;21(19):4373-83. doi: 10.1158/1078-0432.CCR-14-2862. Epub 2015 Apr 21.

47.

MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab.

Harris RJ, Cloughesy TF, Hardy AJ, Liau LM, Pope WB, Nghiemphu PL, Lai A, Ellingson BM.

J Neurooncol. 2015 May;122(3):497-505. doi: 10.1007/s11060-015-1755-8. Epub 2015 Mar 15.

48.

Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab.

Leu K, Enzmann DR, Woodworth DC, Harris RJ, Tran AN, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM.

Cancer Imaging. 2014 Nov 14;14:31. doi: 10.1186/s40644-014-0031-z.

49.

Arterial spin-labeling perfusion MRI stratifies progression-free survival and correlates with epidermal growth factor receptor status in glioblastoma.

Qiao XJ, Ellingson BM, Kim HJ, Wang DJ, Salamon N, Linetsky M, Sepahdari AR, Jiang B, Tian JJ, Esswein SR, Cloughesy TF, Lai A, Nghiemphu L, Pope WB.

AJNR Am J Neuroradiol. 2015 Apr;36(4):672-7. doi: 10.3174/ajnr.A4196. Epub 2014 Dec 26.

50.

Genomics of brain tumor imaging.

Pope WB.

Neuroimaging Clin N Am. 2015 Feb;25(1):105-19. doi: 10.1016/j.nic.2014.09.006. Review.

PMID:
25476516

Supplemental Content

Support Center